![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H23FN4O2 |
Molar mass | 382.439 g·mol−1 |
3D model (JSmol) | |
| |
|
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1][2] In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[3]
The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent[4] and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively.[4][5] ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.[6]
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.[7]
In the United States, ADB-FUBINACA is a Schedule I controlled substance.[8]